COVID-19 neuropathology at Columbia University Irving Medical Center/New York Presbyterian Hospital
Нейропатология COVID-19 в Медицинском центре Колумбийского университета имени Ирвинга/больнице NewYork-Presbyterian
2021-04-12
SCID: 54.1/72c2bjek
Discuss with AI
COVID-19 neuropathologySARS-CoV-2 infectionbrain autopsymicroglial activationviral RNA detection
Figures from the paper
Abstract (AI)
Many patients with SARS-CoV-2 infection develop neurological signs and symptoms; although, to date, little evidence exists that primary infection of the brain is a significant contributing factor. We present the clinical, neuropathological and molecular findings of 41 consecutive patients with SARS-CoV-2 infections who died and underwent autopsy in our medical centre. The mean age was 74 years (38-97 years), 27 patients (66%) were male and 34 (83%) were of Hispanic/Latinx ethnicity. Twenty-four patients (59%) were admitted to the intensive care unit. Hospital-associated complications were common, including eight patients (20%) with deep vein thrombosis/pulmonary embolism, seven (17%) with acute kidney injury requiring dialysis and 10 (24%) with positive blood cultures during admission. Eight (20%) patients died within 24 h of hospital admission, while 11 (27%) died more than 4 weeks after hospital admission. Neuropathological examination of 20-30 areas from each brain revealed hypoxic/ischaemic changes in all brains, both global and focal; large and small infarcts, many of which appeared haemorrhagic; and microglial activation with microglial nodules accompanied by neuronophagia, most prominently in the brainstem. We observed sparse T lymphocyte accumulation in either perivascular regions or in the brain parenchyma. Many brains contained atherosclerosis of large arteries and arteriolosclerosis, although none showed evidence of vasculitis. Eighteen patients (44%) exhibited pathologies of neurodegenerative diseases, which was not unexpected given the age range of our patients. We examined multiple fresh frozen and fixed tissues from 28 brains for the presence of viral RNA and protein, using quantitative reverse-transcriptase PCR, RNAscope® and immunocytochemistry with primers, probes and antibodies directed against the spike and nucleocapsid regions. The PCR analysis revealed low to very low, but detectable, viral RNA levels in the majority of brains, although they were far lower than those in the nasal epithelia. RNAscope® and immunocytochemistry failed to detect viral RNA or protein in brains. Our findings indicate that the levels of detectable virus in coronavirus disease 2019 brains are very low and do not correlate with the histopathological alterations. These findings suggest that microglial activation, microglial nodules and neuronophagia, observed in the majority of brains, do not result from direct viral infection of brain parenchyma, but more likely from systemic inflammation, perhaps with synergistic contribution from hypoxia/ischaemia. Further studies are needed to define whether these pathologies, if present in patients who survive coronavirus disease 2019, might contribute to chronic neurological problems.
Key Findings
1
Brains frequently showed large and small, often haemorrhagic, infarcts and prominent brainstem microglial activation with neuronophagia.
2
In 41 autopsied patients with SARS-CoV-2 infection, hypoxic/ischaemic brain changes were present in every examined brain.
3
Neurodegenerative disease pathologies were detected in 18 patients (44%), consistent with the cohort’s advanced age.
4
Sparse T-lymphocyte accumulation occurred, while no evidence of cerebral vasculitis was identified despite frequent atherosclerosis and arteriolosclerosis.
5
Viral RNA was detectable at low to very low levels in most examined brains, based on PCR analysis of tissues from 28 patients.
Research Object
Brains and neuropathological tissues from deceased patients with SARS-CoV-2 infection undergoing autopsy
Research Subject
Neuropathological and molecular manifestations of COVID-19, including hypoxic/ischaemic injury, infarction, neuroinflammation, neurodegenerative pathology, and the presence of SARS-CoV-2 RNA and protein
Publication Details
Publication Date
2021-04-12
Journal
Publisher
ISSN
Cited by
398
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai7
Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-192020
Invited Review: The spectrum of neuropathology in COVID‐192020
Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study2020
Neuropathology of COVID-19: a spectrum of vascular and acute disseminated encephalomyelitis (ADEM)-like pathology2020
Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China2020
A first case of meningitis/encephalitis associated with SARS-Coronavirus-22020
Neuroinfection may contribute to pathophysiology and clinical manifestations of COVID‐192020
Cited by5
Blood–brain barrier disruption and sustained systemic inflammation in individuals with long COVID-associated cognitive impairment2024
Neurovascular injury with complement activation and inflammation in COVID-192022
Alzheimer's‐like signaling in brains of COVID‐19 patients2022
Neuroinflammation and COVID-192022
Infection of Brain Pericytes Underlying Neuropathology of COVID-19 Patients2021